Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.

Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, Ochsenbauer C, Kappes JC, Krueger W, Worden A, Schneider D, Zhu Z, Orentas R, Dimitrov DS, Goldstein H, Dropulić B.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaav5685. doi: 10.1126/scitranslmed.aav5685.

PMID:
31391322
2.

Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein.

Bardhi A, Wu Y, Chen W, Li W, Zhu Z, Zheng JH, Wong H, Jeng E, Jones J, Ochsenbauer C, Kappes JC, Dimitrov DS, Ying T, Goldstein H.

J Virol. 2017 Sep 27;91(20). pii: e00937-17. doi: 10.1128/JVI.00937-17. Print 2017 Oct 15.

3.

Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA.

J Virol. 2015 Jul;89(13):6685-94. doi: 10.1128/JVI.00474-15. Epub 2015 Apr 15.

5.

Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity.

Ghanem MH, Bolivar-Wagers S, Dey B, Hajduczki A, Vargas-Inchaustegui DA, Danielson DT, Bundoc V, Liu L, Berger EA.

Cytotherapy. 2018 Mar;20(3):407-419. doi: 10.1016/j.jcyt.2017.11.001. Epub 2018 Jan 3.

PMID:
29306566
6.

HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.

Ali A, Kitchen SG, Chen ISY, Ng HL, Zack JA, Yang OO.

J Virol. 2016 Jul 11;90(15):6999-7006. doi: 10.1128/JVI.00805-16. Print 2016 Aug 1.

7.

Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.

Joseph A, Zheng JH, Chen K, Dutta M, Chen C, Stiegler G, Kunert R, Follenzi A, Goldstein H.

J Virol. 2010 Jul;84(13):6645-53. doi: 10.1128/JVI.02339-09. Epub 2010 Apr 21.

8.

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

Schneider D, Xiong Y, Wu D, Nӧlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ.

J Immunother Cancer. 2017 May 16;5:42. doi: 10.1186/s40425-017-0246-1. eCollection 2017.

9.

Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.

Mujib S, Liu J, Rahman AKMN, Schwartz JA, Bonner P, Yue FY, Ostrowski MA.

J Virol. 2017 Jul 27;91(16). pii: e00634-17. doi: 10.1128/JVI.00634-17. Print 2017 Aug 15.

10.

Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.

Brozy J, Schlaepfer E, Mueller CKS, Rochat MA, Rampini SK, Myburgh R, Raum T, Kufer P, Baeuerle PA, Muenz M, Speck RF.

J Virol. 2018 Jun 29;92(14). pii: e00491-18. doi: 10.1128/JVI.00491-18. Print 2018 Jul 15.

11.

Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.

Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, Horvath CJ, Morgan RA.

Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.

12.

Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation.

Kamata M, Kim PY, Ng HL, Ringpis GE, Kranz E, Chan J, O'Connor S, Yang OO, Chen IS.

Biochem Biophys Res Commun. 2015 Jul 31;463(3):216-21. doi: 10.1016/j.bbrc.2015.05.026. Epub 2015 May 19.

13.

Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.

Leibman RS, Richardson MW, Ellebrecht CT, Maldini CR, Glover JA, Secreto AJ, Kulikovskaya I, Lacey SF, Akkina SR, Yi Y, Shaheen F, Wang J, Dufendach KA, Holmes MC, Collman RG, Payne AS, Riley JL.

PLoS Pathog. 2017 Oct 12;13(10):e1006613. doi: 10.1371/journal.ppat.1006613. eCollection 2017 Oct.

14.

In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.

Seay K, Church C, Zheng JH, Deneroff K, Ochsenbauer C, Kappes JC, Liu B, Jeng EK, Wong HC, Goldstein H.

J Virol. 2015 Jun;89(12):6264-74. doi: 10.1128/JVI.00563-15. Epub 2015 Apr 1.

15.

Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.

Haran KP, Hajduczki A, Pampusch MS, Mwakalundwa G, Vargas-Inchaustegui DA, Rakasz EG, Connick E, Berger EA, Skinner PJ.

Front Immunol. 2018 Mar 20;9:492. doi: 10.3389/fimmu.2018.00492. eCollection 2018.

16.

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.

Sautto GA, Wisskirchen K, Clementi N, Castelli M, Diotti RA, Graf J, Clementi M, Burioni R, Protzer U, Mancini N.

Gut. 2016 Mar;65(3):512-23. doi: 10.1136/gutjnl-2014-308316. Epub 2015 Feb 6.

17.

Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.

Hale M, Mesojednik T, Romano Ibarra GS, Sahni J, Bernard A, Sommer K, Scharenberg AM, Rawlings DJ, Wagner TA.

Mol Ther. 2017 Mar 1;25(3):570-579. doi: 10.1016/j.ymthe.2016.12.023. Epub 2017 Jan 28.

18.

Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.

Sloan DD, Lam CY, Irrinki A, Liu L, Tsai A, Pace CS, Kaur J, Murry JP, Balakrishnan M, Moore PA, Johnson S, Nordstrom JL, Cihlar T, Koenig S.

PLoS Pathog. 2015 Nov 5;11(11):e1005233. doi: 10.1371/journal.ppat.1005233. eCollection 2015.

19.

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.

Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang Y, Zhang B, Zhou T, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood J; NISC Comparative Sequencing Program, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ.

J Virol. 2014 Nov;88(21):12669-82. doi: 10.1128/JVI.02213-14. Epub 2014 Aug 20.

Supplemental Content

Support Center